These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7579034)

  • 21. Elimination of liposomal amphotericin by hemodiafiltration.
    Tomlin M; Priestley GS
    Intensive Care Med; 1995 Aug; 21(8):699-700. PubMed ID: 8522680
    [No Abstract]   [Full Text] [Related]  

  • 22. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis.
    Sosa L; Clares B; Alvarado HL; Bozal N; Domenech O; Calpena AC
    Nanomedicine; 2017 Oct; 13(7):2303-2312. PubMed ID: 28712917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence.
    Bellmann R; Egger P; Wiedermann CJ
    Clin Infect Dis; 2003 Jun; 36(11):1500-1. PubMed ID: 12766850
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Amphotericin B--bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B].
    Pleyer U; Grammer J; Pleyer JH; Kosmidis P; Friess D; Schmidt KH; Thiel HJ
    Ophthalmologe; 1995 Aug; 92(4):469-75. PubMed ID: 7549331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 28. Amphotericin B formulations and drug targeting.
    Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
    J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability and transdermal absorption of topical amphotericin B liposome formulations.
    Manosroi A; Kongkaneramit L; Manosroi J
    Int J Pharm; 2004 Feb; 270(1-2):279-86. PubMed ID: 14726142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases.
    Agustin J; Lacson S; Raffalli J; Aguero-Rosenfeld ME; Wormser GP
    Clin Infect Dis; 1999 Sep; 29(3):686-7. PubMed ID: 10530471
    [No Abstract]   [Full Text] [Related]  

  • 31. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 32. [Anti-infectious effect of sustained antravitreal amphotericin B drug delivery system on experimental rabbit fungal endophthalmitis of Candida albicans].
    Chen N; Yang YT; Dong XG; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2006 May; 42(5):420-5. PubMed ID: 16762236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal amphotericin B in neonates with invasive candidiasis.
    Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
    Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.
    Owens D; Fleming RA; Restino MS; Cruz JM; Hurd DD
    Am J Health Syst Pharm; 1997 Mar; 54(6):683-6. PubMed ID: 9075499
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of neonatal candidiasis with liposomal amphotericin B.
    Kapoor D
    Indian Pediatr; 2004 May; 41(5):522-3; author reply 523-5. PubMed ID: 15181316
    [No Abstract]   [Full Text] [Related]  

  • 36. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lipid derivatives of amphotericin B in treatment of systemic candidiasis].
    Rosenthal E
    Presse Med; 2000 Mar; 29(8):428. PubMed ID: 10738509
    [No Abstract]   [Full Text] [Related]  

  • 38. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
    Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
    Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis.
    Kirsh R; Goldstein R; Tarloff J; Parris D; Hook J; Hanna N; Bugelski P; Poste G
    J Infect Dis; 1988 Nov; 158(5):1065-70. PubMed ID: 3183418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
    Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
    Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.